市場調查報告書
商品編碼
1373340
藥物發現外包服務市場-按服務類型(化學、生物)、挖掘類型(小分子和大分子)、疾病模型(體外、細胞和動物模型)、治療領域(糖尿病、神經病學、腫瘤學)、全球預測(2023-2032)Drug Discovery Outsourcing Services Market-By Service Type (Chemistry, Biological), Dug Type (Small & Large-molecule), Disease Model (In-vitro, Cellular & Animal Models), Therapeutic Area (Diabetes, Neurology, Oncology), Global Forecast (2023-2032) |
由於基因療法和單株抗體等生物製劑的快速發展,藥物發現外包服務市場規模從 2023 年到 2032 年的年複合成長率預計將達到 8.2%。
為了滿足個別患者的需求,新型生物製劑和個人化醫療解決方案的蓬勃發展導致生物製藥研發活動對外包服務的需求更大。舉個例子,2021年1月,Charles River Laboratories International與生物製藥服務提供者JADE Biomedical合作,擴大其全球生物製劑測試能力,同時滿足生物製劑治療(主要是細胞和基因療法)的需求。外包提供者對服務的日益關注,例如現實世界的證據生成以及以患者為中心的試驗設計,以提高臨床研究的效率,也將有助於市場的成長。
藥物發現外包服務業根據服務類型、藥物類型、疾病模型、治療領域和區域進行細分。
從服務類型來看,2023-2032年化學服務領域的市場規模將錄得可觀的年複合成長率。藥物發現外包化學服務在製藥和生物技術行業簡化和加快藥物開發過程中發揮關鍵作用。外包計算化學服務以滿足虛擬篩選、分子建模和基於結構的藥物設計等用途的重要性日益凸顯,也將有助於該領域的成長。
以治療領域為基礎,神經病學領域的藥物發現外包服務產業價值預計將擴大到2032年。這一成長可歸因於阿茲海默症、帕金森氏症和多發性硬化症的更高負擔以及隨後的需求開發有效的治療方法。外包神經病學藥物發現服務的一些優點包括加速研發活動、降低成本以及更容易獲得專業知識。
從地區來看,由於存在龐大的人才庫、具有成本效益的勞動力和有利的監管環境,預計到 2032 年,亞太地區藥物發現外包服務市場規模將出現顯著的年複合成長率。對降低成本、獲取專業知識和加速藥物開發過程的日益成長的需求迫使許多製藥和生物技術公司轉向外包藥物發現服務。與智慧財產權、臨床試驗和資料安全相關的不斷變化的監管環境也將促進區域產業的成長。
Drug Discovery Outsourcing Services Market size is poised to record 8.2% CAGR from 2023-2032, on account of the rapid advances in biologics, including gene therapies and monoclonal antibodies.
The surging developments in novel biologics and personalized medicine solutions to cater to individual patients is leading to the greater demand for outsourcing services in biopharmaceutical R&D activities. To cite an instance, in January 2021, Charles River Laboratories International partnered with biopharma service provider JADE Biomedical to expand its global biologics testing capabilities while accommodating the demand for biologics therapeutics, mainly cell and gene therapies. The growing focus of outsourcing providers on services, such as real-world evidence generation as well as patient-centric trial designs for improved efficiency of clinical research will also contribute to the market growth.
The drug discovery outsourcing services industry is segmented based on service type, drug type, disease model, therapeutic area, and region.
In terms of service type, the market size from the chemistry services segment will record appreciable CAGR from 2023-2032. Drug discovery outsourcing chemistry services are playing pivotal role in the pharmaceutical and biotechnology industries in streamlining and expediting the drug development process. The surging importance of outsourcing computational chemistry services to cater to uses in virtual screening, molecular modeling, and structure-based drug design will also contribute to the segment growth.
On the basis of therapeutic area, the drug discovery outsourcing services industry value from the neurology segment is projected to expand up to 2032. The growth can be attributed to the higher burden of Alzheimer's disease, Parkinson's disease, and multiple sclerosis along with the subsequent need for the development of their effective treatments. Accelerated R&D activities, reduces costs, and the improved access to specialized expertise are some advantages of outsourcing neurology drug discovery services.
Regionally, the APAC drug discovery outsourcing services market size is projected to observe notable CAGR through 2032 due to the presence of large talent pools, cost-effective labor, and favorable regulatory environments. The surging need for reducing costs, accessing specialized expertise, and accelerating the drug development process has compelled numerous pharmaceutical and biotechnology companies to turn to outsourcing for drug discovery services. The evolving regulatory landscape related to intellectual property, clinical trials, and data security will also add to the regional industry growth.